Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Defactinib hydrochloride by Verastem for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Defactinib hydrochloride by Verastem for Pancreatic Cancer: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Defactinib hydrochloride by Verastem for Metastatic Melanoma: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Defactinib hydrochloride by Verastem for Colorectal Cancer: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
Defactinib hydrochloride by Verastem for Metastatic Uveal Melanoma: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...
Defactinib hydrochloride by Verastem for Peritoneal Cancer: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase III for Peritoneal Cancer. According to GlobalData, Phase...
Defactinib hydrochloride by Verastem for Fallopian Tube Cancer: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase III for Fallopian Tube Cancer. According to GlobalData,...
Defactinib hydrochloride by Verastem for Ovarian Cancer: Likelihood of Approval
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase...